Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes is a cell therapy designed for its potential antineoplastic activity. It involves harvesting autologous peripheral blood lymphocytes (PBLs) from a patient, which are then genetically modified (transduced) with a retroviral vector. This vector encodes a murine T-cell receptor (mTCR) specifically engineered to recognize and bind to human thyroglobulin (TG) antigen. After transduction, these modified PBLs are expanded in culture and subsequently re-introduced into the patient. The mTCR-expressing PBLs then target and bind to tumor cells that overexpress thyroglobulin, leading to the secretion of cytokines and the lysis of the tumor cells. This approach aims to harness the patient's own immune system to specifically attack thyroglobulin-expressing cancers.
- Other names
- Anti-thyroglobulin mTCR-transduced Peripheral Blood LymphocytesAnti-thyroglobulin mTCR-transduced Peripheral Blood Lymphocytes(NCI)Anti-TG mTCR-transduced PBLAnti-Thyroglobulin mTCR PBL
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes.